Bruker Corporation
BRKR
Pozycja w akcjach
#2331
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Cena akcji
$55.38
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$8.44B
Zmiana (1 dzień)
1.05%
Zmiana (1 rok)
45.30%
Kraj
US
Handel Bruker Corporation (BRKR)
Kategoria
Healthcare
Wskaźnik P/E dla Bruker Corporation (BRKR)
Wskaźnik P/E na dzień October 2026 TTM: -79.54
Według najnowszych raportów finansowych i ceny akcji Bruker Corporation, obecny wskaźnik P/E (TTM) wynosi -79.54. Na koniec 2023 wskaźnik P/E wynosił 25.18.
Historia wskaźnika P/E dla Bruker Corporation od 2000 do 2026
Wskaźnik P/E na koniec każdego roku
| Rok | Wskaźnik P/E | Zmień |
|---|---|---|
| 2026 (TTM) | -79.54 | -202.99% |
| 2024 | 77.23 | 206.68% |
| 2023 | 25.18 | -26.47% |
| 2022 | 34.24 | -25.31% |
| 2021 | 45.85 | -12.87% |
| 2020 | 52.62 | 31.18% |
| 2019 | 40.11 | 55.02% |
| 2018 | 25.88 | -62.52% |
| 2017 | 69.03 | 210.18% |
| 2016 | 22.26 | -44.61% |
| 2015 | 40.18 | -30.80% |
| 2014 | 58.06 | 41.29% |
| 2013 | 41.09 | 25.89% |
| 2012 | 32.64 | 46.67% |
| 2011 | 22.26 | -22.20% |
| 2010 | 28.61 | 17.80% |
| 2009 | 24.28 | 139.77% |
| 2008 | 10.13 | -85.11% |
| 2007 | 68.00 | 64.84% |
| 2006 | 41.25 | -69.31% |
| 2005 | 134.39 | -370.97% |
| 2004 | -49.60 | 85.31% |
| 2003 | -26.76 | -35.09% |
| 2002 | -41.23 | -116.97% |
| 2001 | 243.02 | -58.74% |
| 2000 | 589.00 | 0.00% |
Wskaźnik P/E dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/E | Różnica wskaźnika P/E | Kraj |
|---|---|---|---|
| 33.11 | -141.62% |
US
|
|
| 21.39 | -126.89% |
IE
|
|
| 28.94 | -136.39% |
US
|
|
| 17.34 | -121.80% |
US
|
|
| - | - |
DE
|
Jak odczytywać wskaźnik P/E?
Wskaźnik Cena/Zysk (P/E) mierzy relację między ceną akcji firmy a jej zyskiem na akcję.
Niski, ale dodatni P/E oznacza firmę osiągającą wysokie zyski względem obecnej wyceny i może być niedowartościowana. Wysoki ujemny (bliski 0) P/E wskazuje na duże straty.
Firmy z P/E powyżej 30 lub ujemnym uznaje się zazwyczaj za "akcje wzrostowe", czyli inwestorzy oczekują wzrostu lub przyszłych zysków.
Firmy z dodatnim P/E poniżej 10 uznaje się za "akcje wartościowe", co oznacza, że są już bardzo dochodowe, ale bez dużego potencjału wzrostu.